Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 15/20 | 0.65 |
| ▸ | CHRNB3 | Q05901 | 13/20 | 0.65 |
| ▸ | CHRNA6 | Q15825 | 13/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2935276 | 0.93 | CHRNB2 (0.61) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL7049284 | 0.81 | CHRNB2 (0.75) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1978271 | 0.79 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20186613 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL20186616 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL13478860 | 0.76 | CHRNB2 (0.52) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL27227699 | 0.75 | CHRNB2 (0.48) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL10305115 | 0.74 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16621835 | 0.74 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL16621833 | 0.74 | CHRNB2 (0.44) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| US-8399457-B2 | Pharmaceutical compounds | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2013-03-19 | — | — | US | disclosed |
| EP-2149575-B1 | Diazabicyclic compounds as opioid receptor agonists | NEUROSCIENZE PHARMANESS S C A R L (IT) | 2012-10-24 | — | — | EP | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100029622-A1 | MICROEMULSIONS | NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) | 2010-02-04 | — | — | US | disclosed |
| EP-2149575-A1 | Diazabicyclic compounds as opioid receptor agonists | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-02-03 | — | — | EP | disclosed |
| EP-2149370-A1 | Diazabicyclic compounds and microemulsions thereof | Neuroscienze Pharmaness S.C. A R.L. (IT) | 2010-02-03 | — | — | EP | disclosed |
| US-7358243-B2 | Diazabicyclonane and-decane derivatives and their use as opioid receptor ligands | NEUROSEARCH A/S (DK) | 2008-04-15 | — | — | US | disclosed |
| EP-1527075-B1 | DIAZABICYCLONONANE AND -DECANE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH AS (DK) | 2008-03-26 | — | — | EP | disclosed |
| US-20050239773-A1 | Diazabicyclonane and-decane derivatives and their use as opioid receptor ligands | ANIONA APS (DK) | 2005-10-27 | — | — | US | disclosed |
| EP-1527075-A1 | DIAZABICYCLONONANE AND -DECANE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011468-A1 | DIAZABICYCLONONANE AND -DECANE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | NEUROSEARCH A/S (DK) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100028257-A1 | PHARMACEUTICAL COMPOUNDS | OPRD1, OPRK1, OPRM1 | CHRNB2 70/4885CHRNA3 73/4885CHRNA4 75/4885 |
| US-20100029622-A1 | MICROEMULSIONS | LIPA, APOB, LIPC | CHRNB2 438/4885CHRNA3 520/4885CHRNA4 619/4885 |
| US-20050239773-A1 | Diazabicyclonane and-decane derivatives and their use as opioid receptor ligands | OPRM1, OPRD1, OPRK1 | CHRNB2 131/4885CHRNA3 59/4885CHRNA4 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.